Kynurenines Increase MRS Metabolites in Basal Ganglia and Decrease Resting State Connectivity in Frontostriatal Reward Circuitry in Depression

Xiangchuan Chen, Ph.D.^{1,2}
Diana J. Beltran, B.S.^{1,2}
Valeriya D Tsygankova, B.S.^{1,2}
Bobbi J. Woolwine, L.C.S.W.^{1,2}
Trusharth Patel, M.D.³
Wendy Baer, M.D.²
Jennifer C. Felger, Ph.D.^{1,2}
Andrew H. Miller, M.D.^{1,2}
Ebrahim Haroon, M.D.^{1,2}

1. Emory Behavioral Immunology Program
2. Department of Psychiatry and Behavioral Sciences
3. Department of Anesthesiology,
Emory University School of Medicine
Atlanta, GA 30322

Running Title: Effect of Kynurenines on Glial and Neural Integrity

Address for correspondence:

Ebrahim Haroon, MD
101 Woodruff Circle, Suite 6003
Atlanta, GA 30322,].
Telephone: 404 712-2890
eharoon@emory.edu

Abstract (236):

Inflammation is associated with depressive symptoms including anhedonia in patients with major depression. Nevertheless, the mechanisms by which peripheral inflammatory signals are communicated to the brain to influence central nervous system (CNS) function has yet to be fully elucidated. Based on laboratory animal studies, molecules of the kynurenine pathway (KP), which is activated by inflammation, can readily enter the brain, and generate metabolites that can alter neuronal and glial function, leading to behavioral changes. We therefore examined the relationship between KP metabolites in the plasma and cerebrospinal fluid (CSF) and brain chemistry and neural network function using multi-modal neuroimaging in 49 unmedicated, depressed subjects. CNS measures included 1) biochemical markers of glial dysfunction including glutamate (Glu) and myo-inositol (ml) in the left basal ganglia (LBG) using magnetic resonance spectroscopy (MRS); 2) local activity coherence (regional homogeneity, ReHo) and functional connectivity using resting-state functional magnetic resonance imaging; and 3) anhedonia from the Inventory for Depressive Symptoms-Self Reported. Plasma quinolinic acid (QA) was associated with increases and kynurenic acid (KYNA) and KYNA/QA with decreases in LBG Glu. Plasma kynurenine/tryptophan and CSF 3-hydroxy kynurenine (3HK) were associated with increases in LBG ml. Plasma and CSF KP were associated with decreases in ReHo in LBG and dorsomedial prefrontal cortex (DMPFC), and impaired functional connectivity between these two brain regions. DMPFC-BG connectivity mediated the effect of plasma and CSF KP metabolites on anhedonia. These findings highlight the contribution of KP metabolites to glial and neuronal dysfunction and ultimately behavior in depression.

Introduction (4842 words, formatted):

Previous data has suggested that one mechanism by which inflammation can influence behavior is through effects on brain glutamate (Glu). Chronic administration of the inflammatory cytokine interferon (IFN)-alpha in patients with hepatitis C led to increased Glu in basal ganglia (BG) regions and anterior cingulate cortex (ACC) measured using magnetic resonance spectroscopy (MRS)^{1,2}. Similar increases in BG Glu have also been reported in patients with major depression (MD) with increased endogenous inflammation, indexed by the acute phase reactant c-reactive protein (CRP)³. In each case, increased Glu in these brain regions was associated with increases in the overall severity of depressive symptoms and symptoms of anhedonia, amotivation, and psychomotor slowing¹⁻³. In addition, greater CRP concentrations in the cerebrospinal fluid (CSF) of MD patients were associated with increases in myo-inositol (mI), a marker of astroglial distress in the BG, suggesting that the effects of inflammation upon Glu may reflect alterations in astrocyte function induced by inflammation and oxidative stress^{3,4}.

Relevant to the impact of inflammation on Glu and astrocytic function, there has been an increasing interest in the potential role of metabolites of the kynurenine pathway (KP). Inflammatory stimuli such as lipopolysaccharide (LPS) and Bacillus Calmette–Guérin (BCG) vaccine and inflammatory cytokines such as tumor necrosis factor (TNF) and IFN gamma activate the enzyme indoleamine 2,3 dioxygenase (IDO), which converts tryptophan (TRP) to kynurenine (KYN)⁵⁻⁷. Under homeostatic conditions, ~95% of TRP is converted into KYN, and its breakdown products culminating in the generation of nicotinamide adenine dinucleotide (NAD⁺), an important cellular energy source^{7,8}. KYN is then transported into the brain, where it is metabolized either into 3-hydroxykynurenine (3HK), anthranilic acid (AA), 3-hydroxyanthranilic acid (3HAA), and quinolinic acid (QA) in microglia, tissue macrophages, and trafficking monocytes; or kynurenic acid (KYNA) in astrocytes, oligodendrocytes, and neurons⁸⁻¹². KYN and 3HK gain access to the brain via the large neutral amino acid transporter (LAT-1) in the blood-brain barrier (BBB), leading to an excess of KP metabolism in the brain¹²⁻¹⁴. These data

are consistent with findings in patients with MD, whereby path analyses have demonstrated that increased peripheral blood inflammatory markers are linked to increased peripheral blood KP metabolites that are in turn associated with increased KP metabolites in CSF¹⁵. Of note, in the context of chronic immune activation, astrocytes generate large quantities of KYN that can be converted into QA by adjacent macrophages and microglia¹⁶. KYN can also amplify local proinflammatory signaling via activation of the nod-like receptor protein (NLRP)-2 inflammasome complex in astrocytic cells¹⁷. Astrocytes are responsible for most Glu uptake in synaptic and nonsynaptic areas and, consequently, are the major regulators of Glu homeostasis¹⁸.

KP metabolites influence glutamatergic activity in several distinct ways¹⁹. QA is a well-known endogenous neurotoxin and gliotoxin²⁰. Regarding the impact of KP metabolites on astrocytic regulation of Glu, QA directly promotes astrocytic Glu release, increases its cycling, and decreases its reuptake by astrocytic transporters^{19,20}. 3HK also increases astrocytic Glu release via the induction of reactive oxygen species, leading to activation of the system xC- antiporter, which extrudes one molecule of Glu in exchange for a molecule of cysteine that is used in the synthesis of the antioxidant glutathione^{21,22}. Another target for KP metabolites is the N-methyl-D-aspartate (NMDA)-glutamate receptor on glutamatergic neurons, with QA acting as an agonist and KYNA acting as an antagonist and allosteric modulator at the glycine site^{19,20,22}.

These effects of KP metabolites in conjunction with inflammation on astrocytes and glutamatergic receptor signaling can contribute to excessive Glu release and spillover into the extrasynaptic space^{23,24}. The extrasynaptic diffusion of Glu leads to activation of extrasynaptic NMDA receptors²⁵⁻²⁸, ultimately influencing the concordance and synchrony of BOLD fluctuations between neighboring voxels in resting-state functional MRI (rsfMRI) as reflected by regional homogeneity (ReHo)²⁹. Patterns of spontaneous brain oxygen level-dependent (BOLD) oscillatory activity in rsfMRI³⁰⁻³⁷ provide yet another opportunity to study the relationship between MRS metabolites and functional brain activity. Indeed, MD patients with concurrent

increases in inflammation and CNS Glu exhibited ReHo decreases at the site of MRS acquisition and over a wider network of brain regions, particularly those involved in reward processing²⁹. Impaired connectivity between regions with decreased ReHo was associated with greater depression, anhedonia, and psychomotor slowing²⁹. Our previous data and those from other groups have consistently linked concurrent increases in inflammation and KP metabolism with depression, suicidality, anhedonia, and non-response^{15,38-42}. These findings are also consistent with a rich literature linking the development of depression-like behavior in preclinical models (e.g., decreased sucrose preference, greater immobility on forced-swim or tail-suspension tests) following IDO-activation by inflammatory stimuli^{7,12,43-46}. Finally, in laboratory animals, blocking KP activation through inhibition of IDO or inhibiting the transport of KYN into the brain using leucine or blocking of NMDA receptors with ketamine can reverse inflammation-induced depressive-like behavior^{7,14,44,46}.

Nevertheless, no study has examined the associations of plasma and CSF KP metabolites with MRS and rsfMRI measures (Glu, ml, ReHo, and connectivity) in patients with MD. We, therefore, examined the impact of plasma and CSF KP on brain chemistry and function of BG using MRS and rsfMRI. We hypothesized that increased plasma/CSF KP metabolites would be associated with elevated MRS-signals of astroglial dysfunction (Glu and ml), reduced ReHo, and decreased functional connectivity in BG and other reward-related brain regions, resulting in greater severity of anhedonia. Identifying such a biomarker/neuroimaging-based biosignature could help identify a distinct subgroup of depressed patients with increased inflammation who may respond to KP-targeted pharmacotherapeutics.

Materials and Methods:

Study Sample: We included unmedicated subjects between the ages of 21-65 years with a primary diagnosis of MD based on Structured Clinical Interview for Diagnostic and Statistical Manual-IV (SCID-IV)⁴⁷ and a 17-Item Hamilton Rating Scale for Depression score (HAM-D) ≥ 18 ⁴⁸. Subjects with active suicidal ideation (score >2 on item #3 on HAM-D) were excluded

from study participation and referred for treatment. All qualifying patients were monitored for safety (e.g., suicidality, worsening) and referred for further management if necessary. We determined study eligibility based on history and physical examination, psychiatric evaluation, laboratory testing, and electrocardiography. Presence of Axis I psychiatric disorders (other than anxiety); substance abuse/dependence within the past 6-months (SCID-IV criteria and urine drug testing); unstable medical disorders (needing multiple visits or medication changes); intake of psychotropic medications of any kind (other than prn benzodiazepines, last drug intake > 72 hours prior to assessments); or intake of medications known to affect the immune system (e.g. anti-cytokine therapies, methotrexate, oral steroids, non-steroidal anti-inflammatory agents) were exclusionary. Patients with autoimmune or inflammatory disorders, chronic infections (hepatitis B or C and Human Immunodeficiency Virus) or a history of cancer (other than basal cell skin cancer) were excluded. No individual discontinued their psychotropic medications for the purposes of the study. The Institutional Review Board of Emory University approved the study, and all subjects provided written informed consent. Subjects presented herein represent a subset of patients recruited for an NIH-funded study on phenotyping depressed patients with increased inflammation and overlap with subjects that have appeared in previous reports (NCT01426997)^{3,49}.

Assessment of Depression Severity and Anhedonia: Standardized measures of depression severity were obtained using the 30-item Inventory of Depressive Symptoms - Self-Reported (IDS-SR) – a scale that has been extensively used in previous studies by our and other groups^{3,49-51}. IDS-SR was completed in 1 sitting, and the patients were asked to choose the item response (0, 1, 2, or 3) that best described themselves over the past seven days. The scale was scored by adding 28 of 30 items to obtain a total score ranging from 0-84, excluding items #11-12 (Appetite increase/decrease) and #13-14 (Weight increase/decrease) - per instructions from the developers⁵¹. In addition, items with ambiguous ratings including #9 ('Diurnal Variation of Mood' with two subitems 9A and 9B), #10 ('Quality of Mood' with difficulty in differentiating

depression versus grief), and #25 (Aches and Pains with difficulty in differentiating items from other somatic symptoms) were excluded based on patient feedback. Hierarchical clustering (**Results, Figure 3**) of the remaining 23 individual IDS-SR items indicated that four anhedonia items (#8: “Response to Good or Desired Events,” #17: “View of My Future,” #19: “General Interest Excluding Sex,” and #22: “Interest in Sex”) tightly clustered together. Anhedonia was determined as a factor score representing individual ratings on these four items.

Blood Sampling and Assays: Blood sampling was conducted via an indwelling catheter between 0800-1000hrs, and all subjects sat quietly for 30 minutes before phlebotomy to minimize the impact of circadian variations and stress. The sampled blood was immediately centrifuged at 1000g for 10 minutes at 4°C. Plasma was then removed and frozen at -80°C for batched assays. Lumbar puncture (LP) was performed at the Emory General Clinical Research Center between 1100 and 1500hrs by an attending anesthesiologist one day after blood sampling, as described previously^{15,52}. Approximately 10mL of CSF was collected for each subject after discarding the initial 1mL to avoid blood contamination. Samples were collected into chilled tubes, aliquoted into 1mL vials, and immediately frozen at -80°C until batched assays. **KP assays:** Concentrations of TRP, KYN, KYNA, 3HK, AA, 3HAA, and QA in plasma and the CSF were measured blind to diagnosis by Brains Online, LLC (Charles River, Inc). The plasma and CSF metabolite concentrations were estimated using high-performance liquid chromatography (HPLC) with tandem mass spectrometry (MS/MS) detection using standardized protocol per specifications provided by the vendor. The overall assay CV was <10% for all KP metabolites in the plasma and CSF (see **Supplementary Information 1** for assay details, and **Supplementary Table 1** for assay reliability). All measurements with unreliable quantitation were excluded. KYN/TRP and QA/KYNA ratios were computed for further analyses. **Immune assays:** Based on our previous work showing a strong relationship with KP metabolites in plasma and CSF, TNF and TNF receptor-type-2 (TNFR2) were measured in plasma and CSF based on specifications detailed in our previous studies¹⁵.

MRS/MRI Analysis: MRI scans were acquired using a Siemens 3T Trim-Trio scanner (Siemens Medical Solutions, Malvern, PA, USA). Head motion was limited with foam restraints. T1 images were acquired using MPRAGE sequence (TR/TE/ TI=2300/3.02/1100 ms, flip angle (FA=80°, voxel size= 1x1x1 mm³, matrix size=256x256). rsfMRI data were acquired using an EPI sequence (TR/TE=2950/30 ms, FA=90°, FOV=220 mm, matrix size=3.4x3.4x4.0 mm³, slice number=30, 150 repetitions). Participants were instructed to keep their eyes open and look at a fixed crosshair on the scanner's projection screen. Single-voxel MRS (MRS-SVS) data were acquired using a PRESS sequence (TR/TE=3000/30 ms, FA=90°, sampling size = 1024, size of voxel of interest [VOI]=30x17 x17 mm³, 128 averages with water suppression, 4 with water unsuppressed scans). The VOI was placed in the LBG area (Figure 2A). The preprocessing steps are described in **Supplemental Information 2** and our previous publications^{3,31}. The data were preprocessed by correcting signal spikes, slice-timing shift, and head motion, and removing motion and CSF signals with a general linear model (GLM). The residual time-series data were used to calculate ReHo, converted into the MNI space, and spatially smoothed (full-width half-maximum, FWHM=4 mm). KP-related brain regions of interest (ROIs) were identified by correlating the ReHo results with KP measures. The analysis was conducted using recommended cluster-wise multiple-test correction (voxel-level $p \leq 0.001$ and cluster-wise $p \leq 0.05$ ^{53,54}. ReHo-KP marker correlations were limited to KP metabolites found to be significant in the KP-MRS analysis to avoid multiple comparisons. KP-related ReHo ROIs thus identified were set as seeds for the connectivity analysis. After further removal of the WM signals and temporal filtering (0.01–0.1 Hz), averaged time-series data was calculated for each ReHo ROI and then correlated with the time series data of individual voxels in the brain. Connectivity data from the CSF-KP ReHo ROIs were correlated with the CSF-KP measures, and those from the plasma-KP ReHo ROIs were correlated with the plasma-KP measures. Individual CSF and plasma KP measures were used independently to define both the seed (ReHo ROIs) and their target connectivity ROIs after applying the above-mentioned multiple

correction threshold. Partial-volume correction of absolute quantitation of metabolite concentrations from MRS was performed based on the volumetric ratios of GM, WM, and CSF in the VOI, as described in our earlier publications^{3,29}. See **Supplementary Information 2** for more details of MRI data acquisition and analysis.

Statistical Analysis - Lasso-Inferential Model: Penalizing, cross-fit, partialing-out (double machine learning), lasso-inferential models robust to collinearity were used in Stata v16 (Stata, College Station, TX, USA) to examine the association between MRS markers and KP metabolites after controlling for age, sex, race (Caucasian vs. African American) and body mass index (BMI). Independent models for each of the MRS markers (Glu and ml) and KP metabolites from each compartment (plasma and CSF) were used after partialing out effects of covariate/control variables (age, sex, BMI, and race) per Frisch-Lovell-Waugh theorem. The analysis was geared to test the explanatory power of the primary variables of interest (primary model) and to examine the effect of adding or removing covariates upon these associations (auxiliary model). We conducted this analysis in two phases. The primary model used a plugin estimator consisting of k(10)-fold*resample(10) runs (total=100 runs), and the secondary (sensitivity) analysis used alternate estimators, including cross-validation (CV) and adaptive methods. Of note, noise factors induced by control covariates do not disrupt the primary (plugin) estimator than the auxiliary (cross-validated or adaptive) estimators. **Partial Least Squares - Structural Equation Modeling** (PLS-SEM) was used to examine path effects and mediational associations in Smart PLS⁵⁵. Biomarkers (KP, immune), seed-connectivities, and anhedonia items (of IDS-SR) were used as indicators to generate latent constructs (measurement model) that were further used to test hypotheses based on path associations (structural model). Moderation of these associations by covariates was tested using linear path models for continuously distributed variables (age, BMI) and using group comparison models for categorical covariates (sex, race). The precise details of the measurement and structural model are provided in **Supplemental Information 3**.

Results:

Background Data: Forty-nine subjects with available KP and MRS measures were recruited, of whom 46 subjects with available plasma KP and MRS measures and 40 with KP and rsfMRI measures were included in the study. Details on missing information are provided in

Supplementary Table 1 and Supplementary Information 4. Table 1 provides details of the background demographic, clinical and biological data. None of the missing biomarker data were imputed as it was judged that the missingness was not random. One subject did not answer item #22 on IDS-SR (item on Libido), and the result was imputed using low-rank approximation after verifying it was missing completely at random. The subjects were in moderate to severely depressed range based on HAM-D Scores (mean $\pm$ SD=23.2 $\pm$ 3.2), aged between 21-64 (mean $\pm$ SD=38.6 $\pm$ 10.9 years), and obese (body mass index (BMI)=31.8 $\pm$ 7.9 kg/m²). 69% of the subjects were women, and African Americans comprised 65% of the study population. The high percentage of women is a characteristic of most depressed subject groups, and the high representation of African Americans is consistent with the study location (Atlanta, GA). Several values of CSF KYNA, QA, 3HAA were discarded due to estimation difficulties by BrainsOnline, Inc. Hence only 4 CSF KP metabolites (TRP, KYN, 3HK, and AA) and one ratio (CSF KYN/TRP) were available for analysis.

Plasma KYNA, QA, and KYNA/QA association with MRS Glu: Using the cross-fit, partialing out lasso, plasma QA (**Figure 1A**) was positively (Cf=0.53, 95%CI(0.07,0.99), z=2.41, p=0.024) and plasma KYNA (**Figure 1B**) was negatively (Cf=-0.40, 95%CI=(-0.74,-0.05), z=-2.25, p=0.02) associated with left BG (LBG) Glu. The associations survived multiple testing by K(10)-fold with 10-resamplings of each fold in the primary analysis and during the sensitivity analysis, indicating relative insensitivity to perturbation by covariate induced noise factors. None of the other plasma or CSF metabolites were significantly associated with LBG Glu. Plasma KYNA/QA ratio was negatively associated with LBG Glu (**Figure 1C**, Cf(95%CI)=-0.40(-0.63, -0.16), z=-3.27, p=0.001). The relationship between plasma KYNA/QA was robust (survived 100-fold

resampling) and was not perturbed by adding or removing covariate/control variables during sensitivity analysis using CV and adaptive estimations.

Plasma KYN/TRP and CSF 3HK associations with LBG ml: Plasma KYN/TRP ratio was positively associated with LBG ml ($Cf(95\%CI)=0.25(0.02, 0.48)$, $z=2.17$, $p=0.03$) only in the primary model. This association did not survive sensitivity analysis due to a strong interaction between ml and age. The potent oxidative stress-inducing molecule CSF 3HK (**Figure 1D**) was associated with LBG ml ($Cf(95\%CI)=0.45(0.19, 0.75)$, $z=3.35$, $p=0.001$) in the primary model after 100-fold repetitions. However, this association did not survive sensitivity analysis as age was independently associated with ml, while BMI impacted CSF 3HK. None of the other plasma or CSF KP makers or CSF KYN/TRP were associated with LBG ml.

KP associations with rsfMRI measures (Figure 2, Supplemental Information 6): Based on the above results, only KYN, 3HK, KYNA, QA, KYN/TRP, and KYNA/QA ratios in the plasma, and KYN and 3HK in the CSF were used for ReHo analysis. Plasma QA, KYNA and KYNA/QA yielded ReHo ROIs identical to those provided by KYN and 3HK (provided in **Supplementary Results, Supplementary Figures 2, 3**). Accordingly, ReHo data correlated with plasma KYN, plasma 3HK, CSF KYN, and CSF 3HK were used from all 40 subjects. ReHo ROI correlated with the above 4 markers were used as originating seeds to identify altered connectivity between these and other brain regions as a function of the four KP metabolites. After adjusting for multiple comparisons (voxel $p \leq 0.001$, cluster $p \leq 0.05$), the 4 KP measures were associated with decreased ReHo in a total of 12 ROIs. Besides, 19-decreased seed connectivities between these ROIs and other brain regions were also noted (**Figure 2A**). **Supplementary Information 5, Supplementary Tables 3-4, Supplementary Figures 1** provide a full list of ReHo ROIs and seed connectivities related to the KP metabolites. In terms of voxel volume, ReHo decreases in the DMPFC, and BG together accounted for 62% of total brain wide ReHo decreases identified by all 4 KP metabolites (**Figure 2B**). Additionally, 90% of

seed-connectivity decreases explained by the above 4 KP measures also involved either DMPFC or BG ROIs (**Figure 2C**).

CSF-KP mediates the effects of Plasma KP on DMPFC-BG connectivity (Figure 2D). PLS-SEM was used for path analysis using Baron and Kenny's four-step approach⁵⁶. The mediation model included three factors, i.e., Plasma KP- and CSF KP-factors (latent factors generated from KYN and 3HK from plasma and CSF, respectively), and DMPFC-BG connectivity factor correlated with metabolites used to derive CSF KP latent (including DMPFC-LBG, DMPFC-right (R)BG, LBG-LBG, and LBG-RBG). **Step 1 (path 'c')** examined if there is an effect to mediate. We examined if Plasma KP-latent (predictor variable) was associated with DMPFC-BG connectivity latent. All values reported below were obtained using 10000-bootstrapped repetitions. Plasma KP-factor was associated with DMPFC-BG-factor with a negative path ($Cf(95\%CI)=-0.56(-0.78, -0.37)$, $t=3.36$, $p=0.001$) with a strong effect size ($r-sq=0.31$, Cohen's $f-sq=0.45$). **Step 2 (path 'a')** examined if the predictor variable was correlated with the mediator. We used CSF KP (mediator) as the criterion variable in the path model and Plasma KP as a predictor to estimate and test path 'a'. In line with our previous reports¹⁷, plasma KP-factor was associated with CSF KP-factor via a positive direct path ($Cf(95\%CI)=0.67(0.45, 0.88)$, $t=5.57$, $p<0.001$). **Step 3 (path 'b')** examined if the mediator (CSF KP) affects the outcome variable (DMPFC-BG connectivity latent) after controlling for Plasma KP. We used DMPFC-BG connectivity as the criterion variable in the path model with Plasma KP and CSF KP as predictors. CSF KP was associated with DMPFC-BG connectivity latent via a strong negative effect ($Cf(95\%CI)=-0.67(-0.99, -0.43)$, $t=4.82$, $p<0.001$), after controlling for the effect of Plasma KP-latent. Of note, Plasma KP/DMPFC-BG connectivity association lost its previously noted significance in this step. **Step 4 (path 'c')** tested the hypothesis that CSF KP completely mediates the effect of the Plasma KP/DMPFC-BG relationship. The effect of controlling for CSF KP (mediator variable) would diminish (partial mediation) or nullify (complete mediation) the Plasma KP/DMPFC-BG association. CSF KP-factor exerted a full mediation effect on the

association between plasma KP and DMPFC-BG (path c' , $Cf(95\% CI)=-0.44(-0.89, -0.18)$, $t=2.35$, $p=0.019$). The full-mediation effect by CSF KP on the association between Plasma KP and DMPFC-BG connectivity had strong predictive power and replicability for both in-sample (r -sq difference=0.20, f -sq=0.41) and out-of-sample (blindfolding cross-validation test Q -sq difference=0.22, f -sq=0.34) metrics.

Moderation of KP/Connectivity Associations by immune markers, BMI, and other

covariates: Moderation of above path c' by immune markers (TNF/TNFR2), BMI, age, sex, and race were examined. Plasma TNF/TNFR2 was associated with DMPFC-BG connectivity latent via a negative path ($Cf(95\%CI)=-0.29(-0.55, -0.11)$, $t=2.52$, $p=0.01$). Plasma KP→CSF KP significantly mediated this association with a strong effect size (mediation effect $Cf(95\%CI)=-0.25(-0.57, -0.09)$, $t=2.02$, $p=0.043$, f -sq=0.31). A similar negative indirect association between BMI and DMPFC-BG connectivity was noted ($Cf(95\%CI)=-0.16(-0.39, -0.05)$, $t=2.10$, $p=0.03$), which was similarly mediated by Plasma→CSF KP ($Cf(95\%CI)=-0.16(-0.33,-0.05)$, $t=2.27$, $p=0.023$). Age, sex, and race did not exert moderating effects on the above paths.

DMPFC-BG connectivity/Anhedonia Association: Anhedonia latent was developed using loading from 4 items (#8, 17, 19, 22) of IDS-SR that clustered together during hierarchical clustering, as shown in Figure 3. Item #18: Capacity for Pleasure or Enjoyment was removed following redundancy analysis, as it failed to load adequately in its latent factor (loading coefficient <0.5). 3/19 connectivities correlated with plasma KYN (DMPFC-DMPFC, DMPFC-left ventrolateral prefrontal region, DMPFC-left dorsolateral prefrontal region), and 1/19 related to CSF 3HK (DMPFC-LBG) were selected based on their significant loadings on to the path model predicting Anhedonia Factor (loading coefficient >0.7). **Step 1 (Figure 4A)** examined the direct relationship between KP-associated functional connectivity and Anhedonia. A significant negative association was noted between the DMPFC-BG connectivity factor and the Anhedonia factor ($Cf(95\%CI)=-0.56(-0.77,-0.43)$, $t=6.0$, $p<0.001$), with a strong effect size (r -sq=0.36, Cohen's f -sq= 0.45). **Step 2** involved combining all latent factors (Plasma KP, CSF KP, DMPFC-

BG connectivity, and Anhedonia) within a single unified model, as illustrated in **Figure 4A**. A higher-order path model was used to control for high covariance between plasma and CSF KP metabolites. A combined KP factor including both CSF and Plasma KP ($Cf(95\%)=0.39(0.28, 0.58)$, $t=5.1$, $p<0.001$), plasma KP factor ($Cf(95\%)=0.27(0.20, 0.39)$, $t=5.13$, $p<0.001$), and CSF KP factor ($Cf(95\%)=0.15(0.01, 0.27)$, $t=3.5$, $p<0.001$) were all indirectly associated with Anhedonia. Intriguingly the path from plasma KP to CSF KP to combined KP factor to DMPFC-BG connectivity to Anhedonia was significant ($Cf(95\%)=0.1(0.05, 0.19)$, $t=2.7$, $p=0.007$). The analytic details and loading coefficients are detailed in Supplementary Tables 5-7.

Associations between MRS metabolites and DMPFC-BG connectivity: The details of this analysis are presented in **Supplemental Information 6 and Supplementary Figure 4**.

Power Analysis, Rigor, and Reproducibility: Detailed power estimates and analyses are provided in **Supplemental Figure 5**. Most of our effect sizes (noted in appropriate sections) were in the strong effect size range with Cohen's f^2 values >0.25 . With a sample size of 40, alpha of 0.05, and power of 0.8, effect sizes >0.25 (for direct paths and linear models) and >0.2 (for mediation) were adequate to identify key effects. We have presented data on multiple resampled analyses and sensitivity analyses examining the impact of covariates and disruptive noise factors. The lasso-inferential models used 100-fold resampling of lasso coefficients, and PLS-SEM used 10000-fold bootstrapped CI.

Discussion:

Herein, we report that plasma QA, KYNA, and KYNA/QA were associated with MRS signals of Glu in LBG. Plasma KYN/TRP and CSF 3HK were associated with ml signals in the same region, although this association was subject to moderation by age and BMI. MRS Glu and ml are believed to index astroglial dysfunction and distress^{57,58}. Astroglial dysfunction is a well-documented feature of mood disorders but may be particularly relevant to the inflammatory subtype of MD^{59,60}. The precise nature of the astroglial dysfunction in the inflammatory subtype

of depression is not yet fully clarified. It is now widely accepted that ^1H -MRS primarily measures intracellular Glu that exists at much higher concentrations (5-15 mM) compared with the lower concentrations of Glu ($\sim$ 5-10 μM) encountered in the extracellular space⁶¹. A neuronal-astrocytic neurotransmitter cycle exists in the brain in which Glu from the neuronal pool is released into the synaptic cleft as a neurotransmitter, taken up by astrocytes, converted to glutamine, and returned to the neuron in this synaptically inactive form and converted back to glutamate^{62,63}. Neuronal Glu processing by the astroglia is an energy-intensive process involving an expenditure of 2 molecules of adenosine triphosphate (ATP) for each molecule of glutamate processed⁶². Under mild anesthesia, Glu-glutamine neurotransmitter cycling is believed to consume >80% of total glucose oxidation in the cell⁶². However, the energy costs of glutamate neurotransmission need to be weighed against the energy demands induced by inflammation. For instance, when immune cells are stimulated in vitro, they consume $\sim$ 25-30% more energy, which increases $\sim$ 60% during acute infections⁶⁴. Thus, MRS Glu build-up in inflammation may reflect the impaired processing capacity resulting from astrocytic distress. MRS Glu increases have been reported in various inflammatory and neuropsychiatric disorders⁶⁵. Despite its presence in other tissues, ml is believed to be an astroglial marker as it is highly concentrated in the astroglial cells, as shown in vivo NMR studies^{57,58}. It participates in the osmoregulation of the astrocytic cell and is highly sensitive to inflammation and oxidative stress^{57,58,66}. Increases in ml signals have been associated with immune pathologies such as multiple sclerosis, human immunodeficiency virus (HIV), and hepatitis C virus infections⁶⁶. Intriguingly, it has also been strongly associated with aging and neurodegenerative dementia⁶⁶.

KP metabolism may reflect the convergence of pathologies involving bioenergetic dysfunction, Glu-cycling, and astroglial distress. More recently, the transport of KP molecules across BBB via LAT-1 has been emphasized, as it may be targeted by leucine, a high-affinity blocker of KP transport across LAT-1¹⁴. Upon entry via LAT-1, KYN, and 3HK may bind to the nod-like receptor protein type 2 (NLRP2) in the astrocytes leading to amplification of

neuroinflammatory response via activation of caspase-1 and nuclear factor kappa-B (Nf-Kb), culminating in the release of (IL)1b¹⁷. Thus, kynurenine may by itself act as a danger-associated molecular pattern (DAMP) that stimulates astrocytic inflammation resulting in increases MRS Glu and ml. Basal ganglia is a highly vascularized region with many end arteries offering a rich BBB interface for such pathological immune-KP-brain interactions. Increasing inflammation of the glial cells in the BG region may account for at least some of the reward circuit dysfunction and resultant anhedonia evident in this study.

KP was associated with impaired functional activity and connectivity within/between DMPFC-BG regions, which in turn was associated with anhedonic items of the IDS-SR. Optogenetic experiments indicate that both the top-down (DMPFC Glu systems) and bottom-up (brainstem dopamine systems) compete for functional dominance over the striatal regions to balance competing motivational demands⁶⁷. While the bottom-up inputs convey prediction error reward signals, the top-down inputs adjust and reorient motivational priorities to facilitate longer-term or non-hedonic objectives. For instance, water (during dehydration) or rest (during inflammation and infection) may be preferred over more powerful, reinforcing hedonic stimuli such as sucrose water⁶⁸. Impairments of DMPFC might identify a distinct subgroup of depressed patients who may respond to targeted stimulation of this region⁶⁹⁻⁷¹. DMPFC and its downstream connections have been proposed as promising stimulation targets using transcranial magnetic stimulation (TMS) for anhedonic depression⁷². Our data build upon this developing literature by demonstrating that KP molecules specifically target the DMPFC-BG frontostriatal system.

A major thrust of this study is to focus attention on the anhedonic subtype of depression. Anhedonia refers to a decreased ability to enjoy previously pleasurable experiences experiences⁷³. Anhedonia may be viewed as a transdiagnostic entity seen among many neuropsychiatric disorders⁷⁴⁻⁷⁶. Our data support conceptualizing anhedonia as a dysfunctional integration between top-down and bottom-up networks that regulate reward functions disrupted

by inflammation and its downstream products such as KP molecules^{68,77}. Anhedonia is not only common in late-life depression (rates of ~70%) but appeared to be associated with a ~30% increase in the risk of death and disability among these subjects⁷⁸.

The study's strengths include an in-depth characterization of KP molecules across plasma and CSF compartments, chemical and functional profiling of frontostriatal brain regions, and relating brain changes to anhedonia. However, there are limitations to consider. First, our sample lacks a control group, although we intended to examine KP dysfunction specifically among depressed subjects. Induction of anhedonia among healthy subjects by immune stimulation is well known to engage similar top-down and bottom-up brain circuits⁷⁹⁻⁸². Second, our data is cross-sectional. Longitudinal or interventional studies will provide more insights into the above-noted interactions. Our sample is relatively small, though the effect sizes were strong enough to support the sample size in power analyses. The sample was drawn from and represents a limited universe of medication-free, depressed individuals who were willing to undergo MRI scanning and CSF sampling. Our focus on anhedonia may have excluded other depressive symptom dimensions of interest. Suicidality has been significantly related to KP metabolism over several studies. The recruitment criteria for the study excluded patients with significant suicidal ideation. Finally, given our focus on frontostriatal systems, we did not examine other brain networks.

In conclusion, the study's findings indicate that KP metabolites among depressed subjects were associated with chemical and functional changes in key hub regions of the frontal-subcortical reward system, leading to symptoms of anhedonia. Targeting the peripheral KP system or its transfer into the brain are viable areas of therapeutic interest. Besides, the effect of KP metabolites on brain chemistry may be mitigated by Glu modulating agents such as ketamine and riluzole. Similarly, the newly emerging field of glial protective agents may help ameliorate the toxic effects of inflammation and KP metabolites on the brain.

Funding and Disclosure:

This study was supported by grants R01MH087604 (AHM), R01MH107033 (EH), K23MH091254 (EH), R01MH112076 (AHM, EH), R01MH109637(JCF), R21MH121891 (JCF, AHM), R61MH121625 (JCF) from the National Institute of Mental Health; UL1TR002378 (Georgia Clinical and Translational Alliance, Georgia CTSA) from the National Center for Advancing Translational Sciences, and by a Shared Instrumentation Grant (S10) grant S10OD016413–01 to the Emory University Center for Systems Imaging Core. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Conflict of Interest:

Dr. Miller is a paid consultant to Boehringer Ingelheim. All other authors do not have conflict of interest or financial relationships to disclose.

Table/Figure Legends:

Table 1: Demographic, Clinical and Biological Variables: Legend: Table 1 Abbreviations:

BMI=body mass index, HAMD=17 item Hamilton Depression rating scale, LBG= left basal ganglia, Glu=glutamate, ml=myo-inositol, TNF=tumor necrosis factor, TNFR2=tumor necrosis factor receptor type 2, TRP=tryptophan, KYN=kynurenine, KYNA=kynurenic acid, AA=anthranilic acid, 3HK=3-hydroxy kynurenine, 3HAA=3-hydroxy anthranilic acid, QA=quinolinic acid, CSF=cerebrospinal fluid.

Figure 1: KP-MRS Associations. Legend: Figure 1 represents the partial (A, B) and simple regression plots (C, D) demonstrating the association between kynurenine pathway (KP) metabolites on the x-axis and magnetic resonance spectroscopy (MRS)–based markers in the left basal ganglia on the y-axis. All values were normalized (using Box-Cox Power Transform) and z-scaled. These are simplified least squares models compared with the more complex lasso regression used in the text. **Figure 1A** represents the association between plasma kynurenic acid (KYNA) and LBG glutamate (LBG Glu), **Figure 2B** between plasma quinolinic acid (QA) and LBG glutamate (Glu), **Figure 1C** between plasma KYNA/QA ratio and LBG Glu, and **Figure 1D** between cerebrospinal fluid (CSF) 3-hydroxy kynurenine (3HK) and LBG myo-inositol (LBG ml). The individual coefficients and their significance values are indicated under each graphlet.

Figure 2: KP-Resting fMRI Associations. Legend: Figure 2A presents the primary resting-state functional magnetic resonance imaging (rsMRI) targets of kynurenine pathway (KP) metabolites identified using voxel-based analysis. The areas shaded in deep blue represent the regions of interest (ROI) that demonstrated altered Regional Homogeneity (ReHo) associated with plasma or cerebrospinal fluid (CSF) KP. Identification of ROIs was based on the correlation between kynurenine (KYN) or 3-hydroxy-kynurenine (3HK) in either the plasma or CSF. A

detailed description of all ReHo seed-ROIs thus derived (total = 12 seeds) is presented in **Supplemental Information 4**. ROIs correlated with plasma KP are illustrated using red circles, and CSF KP-related ROIs are illustrated using green circles. These ROIs were also set as the seeds in seed-to-whole brain connectivity analysis. The red or green lines and the red or green uncircled dots represent the connectivity and targets, respectively. Connectivity z-scores correlated with plasma and CSF KP measures were derived after controlling for multiple comparisons (threshold = voxel $p < 0.001$, cluster $p < 0.05$). **Figure 2B** presents a 10x10 dot plot depicting the region-wise distribution of voxels (measured using voxel volume=1 cubic millimeter/voxel), demonstrating ReHo decreases. As is evident, 62% of voxels demonstrating decreased ReHo were located either in the dorsomedial prefrontal cortex (DMPFC), left (LBG), or right basal ganglia (RBG) regions, respectively. **Figure 2C** demonstrates a similar dot plot demonstrating the distribution of KP-correlated connectivity disruptions between ReHo seed regions and other brain regions. As is evident, 95% of whole-brain connectivity decreases were associated with DMPFC-BG regions. **Figure 2D** represents the overall plan of the path/mediation analyses. Plasma and CSF KP latent factors represent the individual contribution of kynurenine (KYN), 3-hydroxy kynurenine (3HK) to each of these factors. DMPFC-basal ganglia (BG) latent factor comprises four different connectivities (DMPFC-LBG, DMPFC-RBG, LBG-LBG, and LBG-RBG). **Path c** examines the relationship between plasma KP and DMPFC-BG connectivity, and **Path a** examines the association between plasma and CSF KP to each other. **Path b** examines if plasma KP impacts the association between CSF KP and DMPFC-BG connectivity. **Path c'** presents the model testing mediation by CSF KP of the relationship between plasma KP on DMPFC-BG connectivity.

Figure 3: Anhedonia – HCA Clustering. Legend: **Figure 3** depicts the dendrogram from hierarchical clustering of individual items on Inventory for Depressive Symptoms-Self Reported (IDS-SR). After removing items with ambiguous and unreliable scoring on IDS-SR (details in

text), the remaining 23 items were clustered using hierarchical clustering with Ward's agglomerative method. As noted, anhedonia items on IDS-SR (items #8, 17, 18, 19, and 22) clustered tightly together and were combined into an 'Anhedonia' factor. Item #18: Capacity for Pleasure or Enjoyment was removed during redundancy analysis, as it failed to load adequately onto its latent factor.

Figure 4: Connectivity-Anhedonia Associations: Legend: **Figure 4A** presents the overall scheme of the path model between all the latent factors within a single, reflective, multi-level path model. Briefly, kynurenine (KYN) and 3-hydroxy-kynurenine (3HK) in plasma and CSF were loaded onto their respective plasma and CSF kynurenine pathway (KP) factors that loaded further onto a combined KP factor. The KP factor was then related to dorsomedial prefrontal (DMPFC)-basal ganglia (BG) latent factor that was further linked to the Anhedonia latent factor described earlier. DMPFC-BG latent factor was composed of both plasma and CSF connectivities selected based on factor loadings (loading coefficient >0.7). 3/4 of the above connectivities, DMPFC-DMPFC (right to left DMPFC), DMPFC-left ventrolateral prefrontal region (LVL PFC), DMPFC-left dorsolateral prefrontal region (DLPFC), were correlated with plasma KYN, and 1/4, i.e., DMPFC-left basal ganglia (LBG) was correlated with CSF 3HK. The red-colored broken lines represent direct paths that combined to create an indirect or mediation effect. Step 1 (**Figure 4A**) examined a direct relationship between functional connectivity and Anhedonia. A significant negative association was noted between the DMPFC-BG connectivity factor and the Anhedonia factor ($r\text{-sq}=0.34$, $p<0.001$, not in the figure). **Figures 4B, 4C, and 4D** represent linear associations between the latent factor scores. **Figure 4B** represents the direct association between KP and DMPFC-BG connectivity, and **Figure 4C** presents the direct association between DMPFC-BG connectivity and Anhedonia. **Figure 4D** represents the indirect association between KP and Anhedonia mediated by DMPFC-BG connectivity. A mediation effect of the link between KP and Anhedonia by connectivity and the relationship between

Plasma KP and Anhedonia by CSF KP and connectivity was significant (details in text).

Table 1: Demographic, Clinical and Biological Variables of the Sample

Variable	N	(%)	Mean(Std Dev)	Min	Max
Age (y)	49		38.6(10.9)	21	64
Female	34	69%			
Male	15	31%			
Caucasian	17	17%			
African American	32	65%			
BMI (kg/m ²)	49		31.8(7.9)	19.6	52.3
HAMD	49		23.2(3.2)	18	32
LBG Glu (mmol/kg)	49		8.7(1)	6.4	10.8
LBG ml (mmol/kg)	49		4.9(0.9)	3.5	7.4
Plasma TNF (pg/ml)	49		5.5(2.2)	0.1	10.6
Plasma TNFR2 (ng/ml)	49		2.5(0.9)	0.8	5.3
Plasma TRP (μM)	49		50.6(8.7)	35	73.4
Plasma KYN (μM)	49		1.6(0.4)	0.9	3.3
Plasma KYNA (nM)	48		37.4(17.7)	13.2	101
Plasma AA (nM)	47		6.1(2.4)	2.6	13.8
Plasma 3HK (nM)	49		32.1(11.4)	12.5	72.5
Plasma 3HAA (nM)	47		20.4(9.4)	8.8	51.4
Plasma QA (nM)	49		432.8(140)	184	733
CSF TRP (μM)	41		1.6(0.4)	0.5	2.5
CSF KYN (nM)	41		32.4(15.6)	13.7	96.2
CSF KYNA (nM)	36		1.5(0.7)	0.7	3.7
CSF AA (nM)	42		2.5(0.8)	1.3	5
CSF 3HKYN (nM)	42		4.8(5.2)	1.3	21.4
CSF QA (nM)	37		20.1(10.6)	10.5	56.7

References

1. Haroon E, Woolwine BJ, Chen X, Pace TW, Parekh S, Spivey JR *et al.* IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. *Neuropsychopharmacology* 2014; **39**(7): 1777-1785.
2. Haroon E, Felger JC, Woolwine BJ, Chen X, Parekh S, Spivey JR *et al.* Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findings. *Brain Behav Immun* 2015; **46**: 17-22.
3. Haroon E, Fleischer CC, Felger JC, Chen X, Woolwine BJ, Patel T *et al.* Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. *Mol Psychiatry* 2016; **21**(10): 1351-1357.
4. Attwells S, Setiawan E, Rusjan PM, Xu C, Hutton C, Rafiei D *et al.* Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder. *Biol Psychiatry* 2020; **88**(8): 649-656.
5. Dantzer R. Role of the Kynurenine Metabolism Pathway in Inflammation-Induced Depression: Preclinical Approaches. *Curr Top Behav Neurosci* 2017; **31**: 117-138.
6. Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. *Curr Opin Pharmacol* 2004; **4**(1): 12-17.
7. O'Connor JC, Andre C, Wang Y, Lawson MA, Szegedi SS, Lestage J *et al.* Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-

- dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. *J Neurosci* 2009; **29**(13): 4200-4209.
8. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ *et al.* Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. *J Neurochem* 2001; **78**(4): 842-853.
 9. Du F, Schmidt W, Okuno E, Kido R, Kohler C, Schwarcz R. Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. *J Comp Neurol* 1992; **321**(3): 477-487.
 10. Wejksza K, Rzeski W, Okuno E, Kandefer-Szerszen M, Albrecht J, Turski WA. Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in oligodendrocyte cell line (OLN-93). *Neurochem Res* 2005; **30**(8): 963-968.
 11. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. *Nat Rev Neurosci* 2012; **13**(7): 465-477.
 12. Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. *Psychoneuroendocrinology* 2011; **36**(3): 426-436.
 13. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. *J Neurochem* 1991; **56**(6): 2007-2017.

14. Walker AK, Wing EE, Banks WA, Dantzer R. Leucine competes with kynurenine for blood-to-brain transport and prevents lipopolysaccharide-induced depression-like behavior in mice. *Mol Psychiatry* 2019; **24**(10): 1523-1532.

15. Haroon E, Welle JR, Woolwine BJ, Goldsmith DR, Baer W, Patel T *et al.* Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. *Neuropsychopharmacology* 2020; **45**(6): 998-1007.

16. Guillemin GJ, Smith DG, Kerr SJ, Smythe GA, Kapoor V, Armati PJ *et al.* Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. *Redox Rep* 2000; **5**(2-3): 108-111.

17. Zhang Q, Sun Y, He Z, Xu Y, Li X, Ding J *et al.* Kynurenine regulates NLRP2 inflammasome in astrocytes and its implications in depression. *Brain Behav Immun* 2020; **88**: 471-481.

18. Matute C, Domercq M, Sanchez-Gomez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. *Glia* 2006; **53**(2): 212-224.

19. Schwarcz R. Kynurenines and Glutamate: Multiple Links and Therapeutic Implications. *Adv Pharmacol* 2016; **76**: 13-37.

20. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. *FEBS J* 2012; **279**(8): 1356-1365.

21. Piani D, Fontana A. Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. *J Immunol* 1994; **152**(7): 3578-3585.

22. Dantzer R, Walker AK. Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression? *J Neural Transm (Vienna)* 2014; **121**(8): 925-932.

23. McCullumsmith RE, Sanacora G. Regulation of extrasynaptic glutamate levels as a pathophysiological mechanism in disorders of motivation and addiction. *Neuropsychopharmacology* 2015; **40**(1): 254-255.

24. Dorsett CR, McGuire JL, DePasquale EA, Gardner AE, Floyd CL, McCullumsmith RE. Glutamate Neurotransmission in Rodent Models of Traumatic Brain Injury. *J Neurotrauma* 2017; **34**(2): 263-272.

25. Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. *Nat Rev Neurosci* 2010; **11**(10): 682-696.

26. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. *Nat Neurosci* 2002; **5**(5): 405-414.

27. Okubo Y, Iino M. Visualization of glutamate as a volume transmitter. *J Physiol* 2011; **589**(Pt 3): 481-488.

28. Sykova E. Extrasynaptic volume transmission and diffusion parameters of the extracellular space. *Neuroscience* 2004; **129**(4): 861-876.
29. Haroon E, Chen X, Li Z, Patel T, Woolwine BJ, Hu XP *et al.* Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia. *Transl Psychiatry* 2018; **8**(1): 189.
30. Biswal BB, Van Kylen J, Hyde JS. Simultaneous assessment of flow and BOLD signals in resting-state functional connectivity maps. *NMR Biomed* 1997; **10**(4-5): 165-170.
31. Bluhm RL, Miller J, Lanius RA, Osuch EA, Boksman K, Neufeld RW *et al.* Spontaneous low-frequency fluctuations in the BOLD signal in schizophrenic patients: anomalies in the default network. *Schizophr Bull* 2007; **33**(4): 1004-1012.
32. Kannurpatti SS, Biswal BB. Detection and scaling of task-induced fMRI-BOLD response using resting state fluctuations. *Neuroimage* 2008; **40**(4): 1567-1574.
33. Lowe MJ, Phillips MD, Lurito JT, Mattson D, Dziedzic M, Mathews VP. Multiple sclerosis: low-frequency temporal blood oxygen level-dependent fluctuations indicate reduced functional connectivity initial results. *Radiology* 2002; **224**(1): 184-192.
34. Cornwell BR, Salvatore G, Furey M, Marquardt CA, Brutsche NE, Grillon C *et al.* Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. *Biol Psychiatry* 2012; **72**(7): 555-561.

35. Hoptman MJ, Zuo XN, Butler PD, Javitt DC, D'Angelo D, Mauro CJ *et al.* Amplitude of low-frequency oscillations in schizophrenia: a resting state fMRI study. *Schizophr Res* 2010; **117**(1): 13-20.

36. Ongur D, Lundy M, Greenhouse I, Shinn AK, Menon V, Cohen BM *et al.* Default mode network abnormalities in bipolar disorder and schizophrenia. *Psychiatry Res* 2010; **183**(1): 59-68.

37. Zuo XN, Di Martino A, Kelly C, Shehzad ZE, Gee DG, Klein DF *et al.* The oscillating brain: complex and reliable. *Neuroimage* 2010; **49**(2): 1432-1445.

38. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G *et al.* CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN- α : relationship to CNS immune responses and depression. *Mol Psychiatry* 2010; **15**(4): 393-403.

39. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D *et al.* Interferon- α -induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. *Biol Psychiatry* 2003; **54**(9): 906-914.

40. Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Traskman-Bendz L, Guillemin GJ *et al.* A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. *Brain Behav Immun* 2015; **43**: 110-117.

41. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M *et al.* Connecting inflammation with glutamate agonism in suicidality. *Neuropsychopharmacology* 2013; **38**(5): 743-752.
42. Savitz J, Dantzer R, Meier TB, Wurfel BE, Victor TA, McIntosh SA *et al.* Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder. *Psychoneuroendocrinology* 2015; **62**: 54-58.
43. Parrott JM, Redus L, Santana-Coelho D, Morales J, Gao X, O'Connor JC. Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation. *Transl Psychiatry* 2016; **6**(10): e918.
44. Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B *et al.* NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. *Neuropsychopharmacology* 2013; **38**(9): 1609-1616.
45. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 2008; **9**(1): 46-56.
46. O'Connor JC, Lawson MA, Andre C, Briley EM, Szegedi SS, Lestage J *et al.* Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. *J Immunol* 2009; **182**(5): 3202-3212.
47. First MB, Spitzer RL, Gibbon M, Williams JB. *Structured Clinical Interview for DSM-IV*. American Psychiatric Press: Washington DC, 1997.

48. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; **23**: 56-62.

49. Felger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X *et al*. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. *Mol Psychiatry* 2016; **21**(10): 1358-1365.

50. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. *Psychol Med* 1996; **26**(3): 477-486.

51. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T *et al*. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. *Psychol Med* 2004; **34**(1): 73-82.

52. Felger JC, Haroon E, Patel TA, Goldsmith DR, Wommack EC, Woolwine BJ *et al*. What does plasma CRP tell us about peripheral and central inflammation in depression? *Mol Psychiatry* 2020; **25**(6): 1301-1311.

53. Cox RW, Chen G, Glen DR, Reynolds RC, Taylor PA. FMRI Clustering in AFNI: False-Positive Rates Redux. *Brain Connect* 2017; **7**(3): 152-171.

54. Eklund A, Nichols TE, Knutsson H. Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. *Proc Natl Acad Sci U S A* 2016; **113**(28): 7900-7905.

55. Ringle CM, Wende S, Becker J-M. "SmartPLS". *Boenningstedt: SmartPLS GmbH*, <http://www.smartpls.com> 2015.

56. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. *J Pers Soc Psychol* 1986; **51**(6): 1173-1182.

57. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. *Dev Neurosci* 1993; **15**(3-5): 289-298.

58. Brand A, Leibfritz D, Richter-Landsberg C. Oxidative stress-induced metabolic alterations in rat brain astrocytes studied by multinuclear NMR spectroscopy. *J Neurosci Res* 1999; **58**(4): 576-585.

59. Torres-Platas SG, Hercher C, Davoli MA, Maussion G, Labonte B, Turecki G *et al*. Astrocytic hypertrophy in anterior cingulate white matter of depressed suicides. *Neuropsychopharmacology* 2011; **36**(13): 2650-2658.

60. Zhang X, Alnafisah RS, Hamoud AA, Shukla R, Wen Z, McCullumsmith RE *et al*. Role of Astrocytes in Major Neuropsychiatric Disorders. *Neurochem Res* 2021.

61. Stagg CJ, Rothman DL. *Magentic Resonance Spectroscopy - Tools for Neuroscience Research and Emerging Clinical Applications*. Academic Press, Inc: London, UK, 2014.
62. Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG.
Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity.
Proc Natl Acad Sci U S A 1998; **95**(1): 316-321.
63. Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. *J Neural Transm (Vienna)* 2014; **121**(8): 799-817.
64. Straub RH. The brain and immune system prompt energy shortage in chronic inflammation and ageing. *Nat Rev Rheumatol* 2017; **13**(12): 743-751.
65. Haroon E, Miller AH, Sanacora G. Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. *Neuropsychopharmacology* 2017; **42**(1): 193-215.
66. Quarantelli M. MRI/MRS in neuroinflammation: methodology and applications. *Clin Transl Imaging* 2015; **3**: 475-489.
67. Ferenczi EA, Zalocusky KA, Liston C, Grosenick L, Warden MR, Amatya D *et al*.
Prefrontal cortical regulation of brainwide circuit dynamics and reward-related behavior.
Science 2016; **351**(6268): aac9698.
68. Treadway MT, Cooper JA, Miller AH. Can't or Won't? Immunometabolic Constraints on Dopaminergic Drive. *Trends Cogn Sci* 2019; **23**(5): 435-448.

69. Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y *et al.* Resting-state connectivity biomarkers define neurophysiological subtypes of depression. *Nat Med* 2017; **23**(1): 28-38.

70. Dunlop K, Talishinsky A, Liston C. Intrinsic Brain Network Biomarkers of Antidepressant Response: a Review. *Curr Psychiatry Rep* 2019; **21**(9): 87.

71. Buch AM, Liston C. Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics. *Neuropsychopharmacology* 2021; **46**(1): 156-175.

72. Downar J, Geraci J, Salomons TV, Dunlop K, Wheeler S, McAndrews MP *et al.* Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. *Biol Psychiatry* 2014; **76**(3): 176-185.

73. DSM-V. *Diagnostic and Statistical Manual of Mental Disorders - V*. 5th edn. American Psychiatric Press, Inc: Washington, DC, USA, 2013.

74. Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity. *JAMA Psychiatry* 2015; **72**(6): 603-611.

75. Cooper JA, Arulpragasam AR, Treadway MT. Anhedonia in depression: biological mechanisms and computational models. *Curr Opin Behav Sci* 2018; **22**: 128-135.

76. Rizvi SJ, Pizzagalli DA, Sproule BA, Kennedy SH. Assessing anhedonia in depression: Potentials and pitfalls. *Neurosci Biobehav Rev* 2016; **65**: 21-35.

77. Lucido MJ, Bekhbat M, Goldsmith DR, Treadway MT, Haroon E, Felger JC *et al.* Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacologic Implications. *Pharmacol Rev*; **Accepted**.

78. Covinsky KE, Cenzer IS, Yaffe K, O'Brien S, Blazer DG. Dysphoria and anhedonia as risk factors for disability or death in older persons: implications for the assessment of geriatric depression. *Am J Geriatr Psychiatry* 2014; **22**(6): 606-613.

79. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. *Biol Psychiatry* 2010; **68**(8): 748-754.

80. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. *Biol Psychiatry* 2009; **66**(5): 407-414.

81. Harrison NA, Cooper E, Dowell NG, Keramida G, Voon V, Critchley HD *et al.* Quantitative Magnetization Transfer Imaging as a Biomarker for Effects of Systemic Inflammation on the Brain. *Biol Psychiatry* 2015; **78**(1): 49-57.

82. Krishnadas R, Harrison NA. Depression Phenotype, Inflammation, and the Brain: Implications for Future Research. *Psychosom Med* 2016; **78**(4): 384-388.